CDEK
← All drugs Report issue

dihydroartemisinin

Small moleculeexperimental

Piperaquine/dihydroartemisinin (DHA/PPQ), sold under the brand name Eurartesim among others, is a fixed dose combination medication used in the treatment of malaria. It is a combination of piperaquine and dihydroartemisinin. Specifically it is used for malaria of the P. falciparum and P. vivax types. It is taken by mouth. — Wikipedia

Clinical trial activity

138 trials · 184 clinical orgs · 0 marketing orgs

Phase 1
11
Phase 2
64
Phase 3
51
Phase 4
43

Earliest trial started May 1, 2003 (NCT00313872)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • Ferriprotoporphyrin IXBINDING AGENT

    Ferriprotoporphyrin IX binding agent

  • Unspecified targetOTHER

    Unknown

  • Unspecified targetUnclear

    Unclear

Chemistry & pharmacology

Loading structure…

SMILES

C[C@H]1[C@@H](O)O[C@@H]2O[C@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3
Mol. weight
284.35 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • alaxin
  • arteether
  • arteether
  • arteether, (3r-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,12ar*))-isomer
  • arteether, (3r-(3alpha,5abeta,6beta,8abeta,9alpha,10beta,12beta,12ar*))-isomer
  • artemisinin, dihydro-
  • artemotil
  • artemotil
  • artemotil
  • artemotil
  • artemotil
  • artemotil
  • artenimol
  • artenimol
  • artenimol
  • artenimol
  • artenimol
  • artether
  • beta-artether
  • beta-dihydroartemisinin
  • cotecxin
  • cotexin
  • dihydroartemisin
  • dihydroartemisin
  • dihydroartemisinin
  • dihydroartemisinin
  • dihydroartemisinin
  • dihydroartemisinin
  • dihydroartemisinin
  • dihydroartemisinin
  • dihydroartemisinine
  • dihydroartemisinine
  • dihydroartemisinin ethyl ether
  • dihydroartemisinin mixture with piperaquine tetraphosphate
  • dihydroqinghaosu
  • dihydroqinghaosu
  • dihydroqinghaosu ethyl ether
  • dihydroquinghaosu
  • dihydroquinghaosu, (3r-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12alpha,12ar*))-isomer
  • dihydroquinghaosu, (3r-(3alpha,5abeta,6beta,8abeta,9alpha,10beta,12alpha,12ar*))-isomer
  • duocotexin
  • duocotexin
  • eurartesim
  • gnf-pf-5634
  • gnf-pf-5634
  • piperaquine tetraphosphate /artenimol
  • quinghaosu, dihydro-
  • sm-227

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07246525Phase 4Dec 1, 2025Government of Uganda, Infectious Disease Institute, Kampala, Uganda, National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco
NCT07021430Early Phase 1 (Phase 1)Oct 31, 2025National Institute of Allergy and Infectious Diseases (NIAID), University of North Carolina at Chapel Hill
NCT06962319Phase 3Sep 30, 2025Medicines for Malaria Venture, University of Liverpool
NCT07007078Early Phase 1 (Phase 1)Jun 30, 2025Fudan University
NCT07082205Phase 3May 2, 2025Centers for Disease Control and Prevention (CDC), National Institute of Allergy and Infectious Diseases (NIAID), University of Liverpool
NCT06870344N/AMar 12, 2025Mbarara University of Science and Technology, National Institute of Allergy and Infectious Diseases (NIAID), North Carolina State University, University of North Carolina at Chapel Hill
NCT06842524Phase 2Mar 1, 2025Fudan University
NCT06083688Phase 4Oct 31, 2024Kamuzu University of Health Sciences, University of Liverpool
NCT07281443N/ASep 23, 2024Cheikh Anta Diop University, Senegal, Government of France, Government of Senegal
NCT06516042Phase 3Aug 21, 2024Government of Ethiopia, PATH
NCT06347471Phase 4May 28, 2024Infectious Disease Institute, Kampala, Uganda, Radboud University, University of London
NCT06417099Phase 2May 24, 2024Fudan University
NCT06068530Phase 4Nov 1, 2023Mahidol University, University of Oxford
NCT05946642Phase 3Jul 15, 2023Malaria Consortium
NCT05788094Phase 4Jun 26, 2023Mahidol University
NCT05980156Phase 4Feb 13, 2023Doris Duke Charitable Foundation, Kamuzu University of Health Sciences, University of Maryland
NCT05829187Phase 2Nov 1, 2022Pancasila University
NCT05426434Phase 3Aug 31, 2022Curtin University, Government of Papua New Guinea, Menzies School of Health Research, University of Liverpool, University of Melbourne
NCT05252845Phase 2Jul 31, 2022Mahidol University, University of Oxford
NCT05465135Phase 4Jul 1, 2022Fudan University
Showing 20 of 138 trials
Page 1 / 7

Organizations

Research & Development (184)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of LondonAcademic/Hospital211342007
University of OxfordAcademic/Hospital191852007
Mahidol UniversityAcademic/Hospital17152007
University of California, San FranciscoAcademic/Hospital161442007
University of LiverpoolAcademic/Hospital161032007
Centers for Disease Control and Prevention (CDC)Government15242007
Makerere UniversityAcademic/Hospital12222007
Kenya Medical Research InstituteAcademic/Hospital10342012
University of MalawiAcademic/Hospital8232010
National Institute for Medical Research, TanzaniaGovernment7342010
Institute of Tropical Medicine, BelgiumAcademic/Hospital6332003
National Institute of Allergy and Infectious Diseases (NIAID)Government6142015
National Institutes of Health (NIH)Government6022010
Radboud UniversityAcademic/Hospital6142009
Wellcome TrustAcademic/Hospital6042004
Bill and Melinda Gates FoundationAcademic/Hospital5022010
Infectious Disease Institute, Kampala, UgandaAcademic/Hospital5122014
Leadiant Biosciences, Inc.For profit5522010
Medicines for Malaria VentureAcademic/Hospital5022010
Fudan UniversityAcademic/Hospital4432022
184 organizations
Page 1 / 10